H3N2 Mutation to Blame for Low Efficacy of 2014-15 Flu Vaccine

This article originally appeared here.
Share this content:
H3N2 Mutation to Blame for Low Efficacy of 2014-15 Flu Vaccine
H3N2 Mutation to Blame for Low Efficacy of 2014-15 Flu Vaccine

MONDAY, June 29, 2015 (HealthDay News) -- A mutation in the H3N2 virus led to a mismatch between it and the H3N2 strain used to create the 2014-2015 vaccine, according to research published June 25 in Cell Reports.

Last season's flu vaccine was less than 20 percent effective, compared with up to 60 percent effectiveness of other seasonal flu vaccines used in the past 10 years, according to the U.S. Centers for Disease Control and Prevention.

It was known that the 2014-2015 vaccine was mismatched with most H3N2 strains circulating during the flu season, but this study is the first to pinpoint the mutation that caused the problem. The finding will help in the development of future seasonal flu vaccines, according to the researchers.

"Flu vaccines work best when they are similar to most circulating flu strains," senior author Scott Hensley, Ph.D., of the Wistar Institute in Philadelphia, said in a journal news release. "The World Health Organization recently recommended that a new H3N2 component should be incorporated into future formulations of seasonal flu vaccines. Our studies support this decision, since most circulating H3N2 strains are mismatched to the 2014-2015 vaccine strain."

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths